Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, 16 September 2022.
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
For patients with non-severe COVID-19, we recommend not to use fluvoxamine, except in the context of a clinical trial
Recommended against
Strong
Notes and Remarks
Remarks
- Several therapeutic options are recommended for patients with non-severe COVID-19 including nirmatrelvir-ritonavir, molnupiravir, and remdesivir.
- For choosing between the therapeutic options, see Section 6.1 and the decision support tool, which displays benefits and harms of the options.
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 14 July 2022.
Year2022
InstitutionWHO
Guideline
Therapeutics and COVID-19: living guideline, 13 January 2023.
Year2023
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 10 November 2023.
Year2023
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, August 2025
Year2025
InstitutionWorld Health Organization